Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies. J of Skin [Internet]. 2024 Nov. 18 [cited 2026 Apr. 17];8(6):s449. Available from: https://skin.dermsquared.com/skin/article/view/3053